Jones from Denmark

Registered at the short selling broker Capital, 3 minutes ago.

» Try Capital you too
71.2% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Vir Biotechnology, Inc. (VIR) shares information

Vir Biotechnology Inc


24h Change

1.49 %

VIR

Live rate: Market closed

Stock data per Wednesday 14 Apr, 2021

VIR
NASDAQ/NGS (GLOBAL SELECT MARKET)
44.88
45.74
45.55
0.67 (+ 1.49%)
US Market is closed

Live Stock price in graph for Vir Biotechnology Inc (VIR)

  • Latest Volume

    841,395 (35.42 %)

  • Volume prev. day

    621,304

  • Avg. daily volume

    780,451

  • Market cap

    5,829,711,603

  • P/E ratio

    n/a

  • Today high

    46.17 USD

  • Today low

    44.52 USD

  • 52 week high

    141.01 USD

  • 52 week low

    25.31 USD

  • YTD Change

    + 71.58 %

Quick links

 

Latest news about Vir Biotechnology Inc

Below you can find the most recent news posts about Vir Biotechnology Inc, primarily from US and UK based news sources.

Vir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 Infection

Monday, 5 April 2021, 15:08:53
Vir Biotechnology Inc (NASDAQ: VIR ) has announced new preclinical data of VIR-7831, the company's investigational monoclonal antibody (mAb) against SARS-CoV-2. The new data showed that the antibody maintains its neutralizing activity against a mutation in the receptor-binding domain (RBD) of SARS-CoV-2, called L452R, found in the California variant (B.1.427/B.1.429). Data from 43 … Full story available on Benzinga.com
— Benzinga


GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug

Friday, 26 March 2021, 17:42:51
GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology Inc. (NASDAQ: VIR ) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investigational dual-action SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with mild-to-moderate COVID-19 who are at risk for a severe worsening of their condition. What Happened: The VIR-7831 project began in April 2020 when the companies began a partnership to develop solutions to combat coronaviruses. The preclinical data suggests VIR-7831 could potentially block viral entry into healthy … Full story available on Benzinga.com
— Benzinga


Can Vir Biotechnology’s share price outperform the biotech theme?

Thursday, 18 March 2021, 13:15:00
Vir Biotech’s share price is the latest stock to see uplift following promising COVID-19 vaccine results.
— CMC Markets


Barclays Stick to Their Buy Rating for Vir Biotechnology By Investing.com

Saturday, 13 March 2021, 02:10:39
Barclays Stick to Their Buy Rating for Vir Biotechnology
— Investing.com


Herbert Virgin Sells 2,340 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Saturday, 13 March 2021, 00:13:32
Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Herbert Virgin sold 2,340 shares of the firm’s stock in a transaction on Wednesday, March 10th. The stock was sold at an average price of $48.00, for a total value of $112,320.00. Following the transaction, the executive vice president now owns 76,540 shares in the company, valued at $3,673,920. The […]
— Watchlist News


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have VIR available or trade one of the many other CFD stocks they have.
Risk warning: 71.2% of retail investor accounts lose money when trading CFDs with Capital.